Literature DB >> 27696248

Influences of the Results from STRIVE Trial on the Combination Androgen Depletion Therapy for Advanced Prostate Cancer.

Hideyuki Akaza1.   

Abstract

The clinical efficacy of combined therapy (CAB) has been clearly recognized by the results of the STRIVE trial. Although enzalutamide has shown a stronger effect on CRPC, bicultamide, a classical anti-androgen, has shown a significant effect. In addition, it can be deduced that CAB is a strong tool for hormone naïve advanced prostate cancer. Cost-effective evaluation for CAB with bicultamide or enzalutamide is warranted, especially for the resource-limited cohort.

Entities:  

Keywords:  Bicultamide; CAB; Cost- effectiveness evaluation; Enzalutamide; STRIVE

Mesh：

Substances：

Year:  2016        PMID： 27696248     DOI： 10.1007/s11934-016-0636-9

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN： 1527-2737            Impact factor:   3.092


  9 in total

1.  The just price of cancer drugs and the growing cost of cancer care: oncologists need to be part of the solution.

Authors:  David G Pfister
Journal:  J Clin Oncol       Date:  2013-09-03       Impact factor: 44.544

Review 2.  Management of prostate cancer in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013.

Authors:  Scott Williams; Edmund Chiong; Bannakij Lojanapiwat; Rainy Umbas; Hideyuki Akaza
Journal:  Lancet Oncol       Date:  2013-11       Impact factor: 41.316

3.  Financial catastrophe, treatment discontinuation and death associated with surgically operable cancer in South-East Asia: Results from the ACTION Study.

Authors:  Stephen Jan; Merel Kimman; Sanne A E Peters; Mark Woodward
Journal:  Surgery       Date:  2015-04-28       Impact factor: 3.982

4.  Enzalutamide in Japanese patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer: A post-hoc analysis of the placebo-controlled PREVAIL trial.

Authors:  Go Kimura; Junji Yonese; Takashi Fukagai; Tomomi Kamba; Kazuo Nishimura; Masahiro Nozawa; Hank Mansbach; Ad Theeuwes; Tomasz M Beer; Bertrand Tombal; Takeshi Ueda
Journal:  Int J Urol       Date:  2016-03-27       Impact factor: 3.369

5.  Trans-Pacific variation in outcomes for men treated with primary androgen-deprivation therapy (ADT) for prostate cancer.

Authors:  Matthew R Cooperberg; Shiro Hinotsu; Mikio Namiki; Peter R Carroll; Hideyuki Akaza
Journal:  BJU Int       Date:  2015-05-14       Impact factor: 5.588

Review 6.  Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma.

Authors:  David J Samson; Jerome Seidenfeld; Brian Schmitt; Vic Hasselblad; Peter C Albertsen; Charles L Bennett; Timothy J Wilt; Naomi Aronson
Journal:  Cancer       Date:  2002-07-15       Impact factor: 6.860

7.  Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.

Authors:  David F Penson; Andrew J Armstrong; Raoul Concepcion; Neeraj Agarwal; Carl Olsson; Lawrence Karsh; Curtis Dunshee; Fong Wang; Kenneth Wu; Andrew Krivoshik; De Phung; Celestia S Higano
Journal:  J Clin Oncol       Date:  2016-01-25       Impact factor: 44.544

8.  Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer.

Authors:  Scott D Ramsey; Aasthaa Bansal; Catherine R Fedorenko; David K Blough; Karen A Overstreet; Veena Shankaran; Polly Newcomb
Journal:  J Clin Oncol       Date:  2016-01-25       Impact factor: 44.544

9.  Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.

Authors:  S Gillessen; A Omlin; G Attard; J S de Bono; E Efstathiou; K Fizazi; S Halabi; P S Nelson; O Sartor; M R Smith; H R Soule; H Akaza; T M Beer; H Beltran; A M Chinnaiyan; G Daugaard; I D Davis; M De Santis; C G Drake; R A Eeles; S Fanti; M E Gleave; A Heidenreich; M Hussain; N D James; F E Lecouvet; C J Logothetis; K Mastris; S Nilsson; W K Oh; D Olmos; A R Padhani; C Parker; M A Rubin; J A Schalken; H I Scher; A Sella; N D Shore; E J Small; C N Sternberg; H Suzuki; C J Sweeney; I F Tannock; B Tombal
Journal:  Ann Oncol       Date:  2015-06-03       Impact factor: 32.976
  9 in total
  1 in total

1.  Treatment sequence in castration-resistant prostate cancer: A retrospective study in the new anti-androgen era.

Authors:  Senji Hoshi; Kenji Numahata; Kunio Ono; Nobuhiro Yasuno; Vladimir Bilim; Kiyotsugu Hoshi; Hiroshi Amemiya; Isoji Sasagawa; Shoichiro Ohta
Journal:  Mol Clin Oncol       Date:  2017-08-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.